These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 15209772)

  • 1. Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with Type 1 diabetes.
    Heller SR; Colagiuri S; Vaaler S; Wolffenbuttel BH; Koelendorf K; Friberg HH; Windfeld K; Lindholm A
    Diabet Med; 2004 Jul; 21(7):769-75. PubMed ID: 15209772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes.
    Kølendorf K; Ross GP; Pavlic-Renar I; Perriello G; Philotheou A; Jendle J; Gall MA; Heller SR
    Diabet Med; 2006 Jul; 23(7):729-35. PubMed ID: 16842476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes.
    Christiansen JS; Vaz JA; Metelko Z; Bogoev M; Dedov I
    Diabetes Obes Metab; 2003 Nov; 5(6):446-54. PubMed ID: 14617231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.
    Hermansen K; Fontaine P; Kukolja KK; Peterkova V; Leth G; Gall MA
    Diabetologia; 2004 Apr; 47(4):622-9. PubMed ID: 15298338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glargine versus NPH insulin: efficacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes--the glargine and aspart study (GLASS) a randomised cross-over study.
    Chatterjee S; Jarvis-Kay J; Rengarajan T; Lawrence IG; McNally PG; Davies MJ
    Diabetes Res Clin Pract; 2007 Aug; 77(2):215-22. PubMed ID: 17141354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus.
    Chapman TM; Noble S; Goa KL
    Drugs; 2002; 62(13):1945-81. PubMed ID: 12215068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial.
    Kaneko S; Chow F; Choi DS; Taneda S; Hirao K; Park Y; Andersen TH; Gall MA; Christiansen JS;
    Diabetes Res Clin Pract; 2015 Jan; 107(1):139-47. PubMed ID: 25498130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial.
    Liebl A; Prager R; Binz K; Kaiser M; Bergenstal R; Gallwitz B;
    Diabetes Obes Metab; 2009 Jan; 11(1):45-52. PubMed ID: 18643839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Counter-regulatory hormone responses to spontaneous hypoglycaemia during treatment with insulin Aspart or human soluble insulin: a double-blinded randomized cross-over study.
    Brock Jacobsen I; Vind BF; Korsholm L; Flyvbjerg A; Frystyk J; Holst JJ; Beck-Nielsen H; Henriksen JE
    Acta Physiol (Oxf); 2011 Jul; 202(3):337-47. PubMed ID: 21481195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin.
    Porcellati F; Rossetti P; Pampanelli S; Fanelli CG; Torlone E; Scionti L; Perriello G; Bolli GB
    Diabet Med; 2004 Nov; 21(11):1213-20. PubMed ID: 15498088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.
    Fulcher GR; Gilbert RE; Yue DK
    Intern Med J; 2005 Sep; 35(9):536-42. PubMed ID: 16105155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes.
    Franek E; Haluzík M; Canecki Varžić S; Sargin M; Macura S; Zacho J; Christiansen JS
    Diabet Med; 2016 Apr; 33(4):497-505. PubMed ID: 26435365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin analogues in children with Type 1 diabetes: a 52-week randomized clinical trial.
    Thalange N; Bereket A; Larsen J; Hiort LC; Peterkova V
    Diabet Med; 2013 Feb; 30(2):216-25. PubMed ID: 23094597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin during pregnancy, labour and delivery.
    de Valk HW; Visser GH
    Best Pract Res Clin Obstet Gynaecol; 2011 Feb; 25(1):65-76. PubMed ID: 21186142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does insulin lispro preserve the physiological defences to hypoglycaemia during intensive insulin therapy with a conventional basal bolus regimen?
    Heller SR; Amiel SA; Evans ML; Kong MF; Macdonald IA; Peacey SR
    Diabetes Obes Metab; 2002 Mar; 4(2):106-12. PubMed ID: 11940107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial.
    Bartley PC; Bogoev M; Larsen J; Philotheou A
    Diabet Med; 2008 Apr; 25(4):442-9. PubMed ID: 18387078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial.
    Lund SS; Tarnow L; Frandsen M; Nielsen BB; Hansen BV; Pedersen O; Parving HH; Vaag AA
    BMJ; 2009 Nov; 339():b4324. PubMed ID: 19900993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin.
    De Leeuw I; Vague P; Selam JL; Skeie S; Lang H; Draeger E; Elte JW
    Diabetes Obes Metab; 2005 Jan; 7(1):73-82. PubMed ID: 15642078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial.
    Home PD; Lindholm A; Riis A;
    Diabet Med; 2000 Nov; 17(11):762-70. PubMed ID: 11131100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Additional lunchtime basal insulin during insulin lispro intensive therapy in a randomized, multicenter, crossover study in adults : a real-life design.
    Stades AM; Hoekstra JB; van den Tweel I; Erkelens DW; Holleman F;
    Diabetes Care; 2002 Apr; 25(4):712-7. PubMed ID: 11919130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.